Abstract
Head and neck squamous cell cancer is the sixth most common cancer worldwide. Surgical management is effective as a single modality only for early-stage cancers (30% of patients). Making progress in this cancer is of vital interest. The standard treatment for advanced disease is chemoradiotherapy, with the goal of palliation of symptoms and prolongation of life. Response rates to even the best of regimens are approximately 30-40%, with the median survival period of approximately 6 months. Various approaches to treatment of recurrent disease are under investigation, including new drugs or combinations of drugs, with radiotherapy.
| Original language | English |
|---|---|
| Pages (from-to) | 111-115 |
| Number of pages | 5 |
| Journal | Expert Review of Anticancer Therapy |
| Volume | 1 |
| Issue number | 1 |
| Publication status | Published - 2001 |
Keywords
- 5-Fluorouracil
- Chemoradiotherapy
- Cisplatin
- Gemcitabine
- Head and neck squamous cell cancer
- Irinotecan
- Taxanes
ASJC Scopus subject areas
- Cancer Research
- Pharmacology
Fingerprint Dive into the research topics of 'New chemoradiotherapy combinations in head and neck cancer'. Together they form a unique fingerprint.
Cite this
Busto, G., Corvò, R., Ricci, I., Sanguineti, G., & Benasso, M. (2001). New chemoradiotherapy combinations in head and neck cancer. Expert Review of Anticancer Therapy, 1(1), 111-115.